CHD2
CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
Overview
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression.
IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Gastrointestinal Stromal Tumour, Papillary Renal Cell Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
- 1 · What it is
CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.
- 2 · What goes wrong in cancer
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3.
- 3 · How drugs use it
No product in this corpus aims at CHD2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:1917 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14647 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000173575 (per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.72, B-cell chronic lymphocytic leukaemia 0.71, non-Hodgkin lymphoma 0.72, leukaemia 0.74 (GraphQL API, CC0)); IntOGen CHD2 (driver in 7 cohorts (Act 3, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression. Location: Nucleus (UniProt). Locus 15q26.1 (HGNC).
- Leukaemia: Open Targets association 0.74 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.72 with non-Hodgkin lymphoma (MONDO_0018908)
- Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)
- Acute lymphoblastic leukaemia: Open Targets association 0.72 with acute lymphoblastic leukaemia (MONDO_0004967)
- Chronic lymphocytic leukaemia: Open Targets association 0.71 with B-cell chronic lymphocytic leukaemia (MONDO_0004948); IntOGen driver in 4 cohorts (CLLSLL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 4 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CHD2" OR ABSTRACT:"CHD2" OR TITLE:"chromodomain helicase DNA binding protein 2" OR ABSTRACT:"chromodomain helicase DNA binding protein 2" OR TITLE:"ATP-dependent chromatin remodeler CHD2" OR ABSTRACT:"ATP-dependent chromatin remodeler CHD2" OR TITLE:"FLJ38614" OR ABSTRACT:"FLJ38614" OR TITLE:"DKFZp547I1315" OR ABSTRACT:"DKFZp547I1315" OR TITLE:"DKFZp781D1727" OR ABSTRACT:"DKFZp781D1727") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CHD2, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNUP214
Shares Papillary renal cell carcinoma, Leukaemia (all types), Renal cell carcinoma, Non-Hodgkin lymphoma (all types).
- TargetCNOT3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetPIK3CG
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetRPL10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetSGK1
Shares Papillary renal cell carcinoma, Renal cell carcinoma, Non-Hodgkin lymphoma (all types), IntOGen.
- TargetBIRC3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.